Expert Interview
A look at Ultragenyx setrusumab (UX143) for the treatment of osteogenesis imperfecta ahead of the Phase 3 clinical trial readout
Ticker(s): RARE, MREOInstitution: Children’s Mercy Kansas City
- Clinical geneticist specializing in rare bone disorders including hypophosphatasia and osteogenesis imperfecta, with board certifications in pediatrics, internal medicine, and clinical genetics
- Treats a broad population of patients with skeletal dysplasias and other complex genetic bone diseases each year through the Skeletal Dysplasia Clinic
- Primary research focus is on the diagnosis and treatment of genetic bone disorders, with extensive contributions to the field including more than 70 publications
How would you compare the mechanism of action of setrusumab, as an anti-sclerostin antibody, to current standards of care such as bisphosphonates or teriparatide in pediatric and young adult OI patients?
Added By: sara_adminWhat data from the Phase 3 portion of the ORBIT study would be most important for you when considering setrusumab for routine clinical use?
Added By: sara_adminWhat unmet needs remain in the management of OI across different subtypes and age groups, and how do you see a therapy like setrusumab potentially changing long-term care?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
